|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home > News
|
Search here for news related to drugs, alcohol, and tobacco.
|
|
|
|
Customize the news based on countries, topics and information
type. Use the Ctrl key to select more than one item in a box.
|
|
|
|
|
(Select multiple by holding down Ctrl key)
|
|
|
|
|
|
|
Country:
|
|
Topic:
|
|
Organization*:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Search Keyword(s):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Customize the news based on countries, topics and information type. |
New book on role of CBOs and NGOs in global public health
Igniting the Power of Community: The Role of CBOs and NGOs in Global Public Health is a new book edited by Paul Gaist, PhD, MPH, adjunct professor at the Johns Hopkins Bloomberg School of Public Health, which explores the pursuits and potential of community-based organizations (CBOs) and nongovernmental organizations (NGOs) to transform global public health. more... |
Survey underscores need for continued efforts to combat substance abuse among teens
New survey data released today by the Partnership for a Drug-Free America and MetLife Foundation point to the need for continued efforts to combat substance abuse among teens. While there was no significant increase in the abuse of over-the-counter (OTC) cough medicines containing dextromethorphan, the 21st annual Partnership/MetLife Foundation Attitude Tracking Survey (PATS) found an overall waning in teens' negative perceptions about many drugs along with increases in abuse rates for alcohol, ecstasy, and marijuana. more... |
Merck’s MF/F Phase III study data presented at AAAAI annual meeting
Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. more... |
Of the 2.3M inmates, only 1.5M meet DSM IV medical criteria for substance abuse: CASA
Of the 2.3 million inmates crowding our nation's prisons and jails, 1.5 million meet the DSM IV medical criteria for substance abuse or addiction, and another 458,000, while not meeting the strict DSM IV criteria, had histories of substance abuse; were under the influence of alcohol or other drugs at the time of their crime; committed their offense to get money to buy drugs; were incarcerated for an alcohol or drug law violation; or shared some combination of these characteristics, according to Behind Bars II: Substance Abuse and America's Prison Population. Combined these two groups constitute 85 percent of the U.S. prison population. more... |
Neurogenesis linked to drug addiction and relapse
Researchers at UT Southwestern Medical Center hope they have begun paving a new pathway in the fight against drug dependence. Their hypothesis - that increasing the normally occurring process of making nerve cells might prevent addiction - is based on a rodent study demonstrating that blocking new growth of specific brain nerve cells increases vulnerability for cocaine addiction and relapse. more... |
The Coalition for Evidence-Based Policy selects Botvin LST as "Top Tier" program
Botvin LifeSkills Training has been selected as a "Top Tier" program by The Coalition for Evidence-Based Policy. The Top Tier initiative, which is being followed closely by Congress, focuses on identifying and validating social programs meeting the highest standard of evidence of effectiveness. more... |
ONDCP, HHS announce availability of over $1.1M for new Drug Free Communities Support programs
The White House Office of National Drug Control Policy (ONDCP) and the U.S. Department of Health and Human Services (HHS) is announcing the availability of more than $1.1 million for new Drug Free Communities Support Mentoring program (DFC Mentoring) grants. An estimated 15 new Mentoring grants will be awarded (up to $75,000 per grant, per year) to drug and alcohol prevention community coalitions from across the nation. The length of the project period is up to two years. more... |
LifeSciences British Columbia, UBC to host global summit on HIV/AIDS
LifeSciences British Columbia, the BC Centre of Excellence in HIV/AIDS, and the University of British Columbia will host a global summit on HIV/AIDS on Feb. 26th, 2010, against the backdrop of the 2010 Olympic Games. more... |
Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction
Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost. more... |
FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE). more... |
| Previous |
Next |
| Go to page |
| Page 1 of 21 |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|